Immunophage Biomedical Co. Ltd. has divulged G-protein coupled receptor 183 (GPR183; EBI2) antagonists reported to be useful for the treatment of autoimmune disease, cancer, liver diseases, osteoporosis and neuropathic pain.
Immunophage Biomedical Co. Ltd. has synthesized macrophage migration inhibitory factor (MIF) inhibitors reported to be useful for the treatment of cancer and inflammation.
Synthesis and optimization of several series of G-protein coupled receptor 183 (GPR183) antagonists at Immunophage Biomedical Co. Ltd. led to the discovery of a lead candidate with promising potency (IC50=31.3 nM), reduced hERG inhibition and improved aqueous solubility.
Researchers from Immunophage Biomedical Co. Ltd. have published details on the discovery and preclinical evaluation of a new CD38 inhibitor being developed for the treatment of mitochondrial myopathy.
Immunophage Biomedical Co. Ltd. has identified ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 (CD38) inhibitors reported to be useful for the treatment of cancer, neurodegeneration, and inflammatory, autoimmune and metabolic disorders.
Chemokine (C-C motif) receptor 8 (CCR8), a member of the β chemokine receptor family, contributes to the recruitment and immunosuppressive function of regulatory T (Treg) cells within the tumor microenvironment.
Immunophage Biomedical Co. Ltd. have prepared and tested G-protein coupled receptor 183 (GPR183; EBI2) antagonists that are reported to be useful for the treatment of autoimmune disease, cancer, liver diseases, osteoporosis and neuropathic pain.
